An observational study in Arrhythmogenic Cardiomyopathy, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to describe the clinical phenotypes, natural history, and long-term outcomes of arrhythmogenic cardiomyopathy (ACM) in patients of all ages.
The main questions it aims to answer are:
Researchers will observe patients with different ACM phenotypes to better understand their disease progression and long-term outcomes. No experimental treatments will be assigned.
Participants will:
Background and Rationale
Arrhythmogenic cardiomyopathy (ACM) is a heterogeneous group of myocardial diseases characterized by a predisposition to ventricular arrhythmias, sudden cardiac death, and progressive ventricular dysfunction. ACM may predominantly affect the right ventricle, left ventricle, or both ventricles. Its clinical manifestations, genetic backgrounds, patterns of myocardial involvement, and rates of disease progression vary considerably among affected individuals.
Despite advances in genetic testing, cardiac imaging, and clinical management, the natural history and long-term outcomes of ACM remain incompletely characterized, particularly across different ventricular phenotypes, age groups, and genetic backgrounds. Longitudinal multicenter data are needed to better understand disease progression, major ventricular arrhythmic events, heart failure-related outcomes, and changes in cardiac structure and function.
Study Objectives
The STARTER Registry aims to systematically characterize the clinical phenotypes, natural history, and long-term outcomes of patients with ACM. Particular emphasis is placed on serious ventricular arrhythmias, sudden cardiac death, heart failure-related events, and longitudinal changes in ventricular structure and function.
The study also aims to establish a standardized clinical database linked to an optional biological sample repository to support future clinical and translational research, subject to appropriate ethical approval and participant authorization.
Study Design and Population
STARTER is an investigator-initiated, multicenter, observational, retrospective and prospective registry cohort study led by the First Affiliated Hospital of Xi'an Jiaotong University.
The registry will include approximately 4,500 patients with a clinical diagnosis of ACM, without restrictions on age or sex. Eligible patients include those previously diagnosed with ACM, those currently receiving follow-up care, and newly diagnosed patients.
The diagnosis of ACM will be established through comprehensive clinical evaluation, incorporating medical and family history, electrocardiographic findings, cardiac imaging, genetic testing when available, and histopathological findings when clinically indicated. Diagnostic assessment will refer to established international guidelines and consensus documents, including the 2019 Heart Rhythm Society expert consensus statement, the 2020 Padua criteria, the 2023 European Society of Cardiology guidelines for cardiomyopathies, and applicable updated diagnostic standards.
Patients will be primarily classified into three ventricular phenotype categories:
Additional analyses may examine differences according to genetic background, age, ventricular arrhythmia history, cardiac magnetic resonance findings, ventricular function, and clinical disease stage. These classifications are observational and do not determine treatment allocation.
Retrospective and Prospective Cohorts
The retrospective component will include eligible patients with available clinical records from January 1, 2018, through October 1, 2026. Previously collected clinical information, diagnostic investigations, treatment records, and documented clinical outcomes will be reviewed.
The prospective component will enroll eligible patients following the required ethical approvals and will continue recruitment through December 31, 2045.
Each patient will generally undergo a core observation period of 5 years, with follow-up assessments at approximately 6 months, 12 months, and annually during years 2 through 5. Extended follow-up may be conducted when applicable,
49 studies on the registry are indexed under Arrhythmogenic Right Ventricular Dysplasia; 29 are open to participants now.
This study's planned enrollment of 4,500 is above the median of 336 across 34 observational studies indexed under Arrhythmogenic Right Ventricular Dysplasia.
Browse Arrhythmogenic Right Ventricular Dysplasia studies →First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 318 studies on the registry; 91 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 18, 2026. See what changed
The study population consists of patients of all ages with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM) receiving care at the First Affiliated Hospital of Xi'an Jiaotong University and participating medical centers in China. The registry includes patients with previously established ACM, patients undergoing ongoing clinical follow-up, and newly diagnosed patients. Eligible participants will be identified through routine clinical practice and existing medical records. Both retrospective and prospective cohorts will be included. Patients may present with right-dominant, left-dominant, or biventricular ACM phenotypes. Enrollment does not require genetic testing, cardiac magnetic resonance imaging, or biological sample collection. Patients will be enrolled consecutively when eligible, and unique study identifiers will be used to avoid duplicate enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional Considerations:
Patients with coexisting diseases, previous ventricular arrhythmias, implantable cardioverter-defibrillators, prior catheter ablation, or heart failure may be eligible if they otherwise meet the study criteria.
Cardiac magnetic resonance imaging, genetic testing, and biological sample collection are not mandatory for enrollment. The absence of these investigations or samples will not be considered an exclusion criterion.
Asymptomatic relatives carrying ACM-associated genetic variants who do not meet the clinical diagnostic criteria for ACM will not be included in the confirmed ACM registry cohort solely on the basis of carrier status.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients of all ages with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM) and available medical records from January 1, 2018, through October 1, 2026, will be included retrospectively. Existing clinical data, including medical history, ventricular phenotype, electrocardiographic findings, cardiac imaging, genetic testing results when available, treatments, and documented clinical outcomes, will be collected and analyzed. Patients will be classified according to right-dominant, left-dominant, or biventricular ACM phenotypes. No research-specific interventions, additional examinations, or new biospecimen collection will be performed as part of retrospective data collection.
Patients of all ages with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM) will be prospectively enrolled and followed under routine clinical care. Clinical, electrocardiographic, imaging, genetic, treatment, and outcome data will be collected. Patients will be classified as having right-dominant, left-dominant, or biventricular ACM. Follow-up will generally occur at 6 months, 12 months, and annually during years 2 through 5 to assess serious ventricular arrhythmias, sudden cardiac death, heart failure-related events, and changes in cardiac phenotype. Optional biospecimens may be collected with appropriate consent and ethical approval. No experimental treatments or research-mandated invasive procedures will be performed.
Time to First Composite Serious Ventricular Arrhythmic Event
Time from cohort entry to the first occurrence of a composite serious ventricular arrhythmic event, defined as sustained ventricular tachycardia (VT), ventricular fibrillation (VF), successfully resuscitated cardiac arrest, appropriate implantable cardioverter-defibrillator (ICD) therapy, or sudden cardiac death. Sustained VT is defined as lasting at least 30 seconds or requiring earlier termination because of hemodynamic instability. Appropriate ICD therapy includes antitachycardia pacing or shock delivered for a confirmed ventricular tachyarrhythmia. Events occurring before cohort entry will be recorded separately and will not be counted as incident events.
Time frame: Time to First Composite Serious Ventricular Arrhythmic Event
First Occurrence of Sustained Ventricular Tachycardia or Ventricular Fibrillation
Time from cohort entry to the first occurrence of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) during follow-up, documented by electrocardiography, ambulatory rhythm monitoring, implanted cardiac devices, or other available clinical records. Sustained VT is defined as lasting at least 30 seconds or requiring earlier termination because of hemodynamic instability. The date and type of the first qualifying event will be recorded.
Time frame: 5 years
Incidence of Sudden Cardiac Death
Sudden cardiac death during follow-up, assessed using available medical records, circumstances of death, and other supporting clinical information. Events will be classified according to standardized adjudication criteria, including documented or clinically suspected sudden cardiac death when supported by available evidence.
Time frame: 5 years
First Occurrence of Appropriate Implantable Cardioverter-Defibrillator Therapy
Time from cohort entry to the first occurrence of appropriate ICD therapy, including antitachycardia pacing or shock delivered for a documented ventricular tachyarrhythmia, as confirmed by available device interrogation records and clinical review. Inappropriate ICD therapies will not be counted. This outcome will be evaluated among patients with an ICD during the observation period.
Time frame: 5 years
Occurrence of Heart Failure Hospitalization
Occurrence of hospitalization for worsening heart failure after cohort entry, identified from hospital records and follow-up information. Heart failure hospitalization will be evaluated as a separate clinical outcome, with the date of the first qualifying admission recorded.
Time frame: 5 years
All-Cause Mortality
Occurrence of death from any cause after cohort entry during follow-up. The date of death will be determined from available medical records, follow-up information, and other approved sources. All deaths will be included regardless of the underlying cause.
Time frame: 5 years
Cardiovascular Mortality
Occurrence of death attributed to cardiovascular causes after cohort entry during follow-up. The date and cause of death will be determined using available medical records, follow-up information, and other supporting clinical information. Cardiovascular mortality will be classified separately from noncardiovascular mortality whenever sufficient information is available.
Time frame: 5 years
Occurrence of Heart Transplantation
Occurrence of heart transplantation after cohort entry during follow-up, as documented in clinical records. The date of transplantation will be recorded.
Time frame: 5 years
Initiation of Long-Term Mechanical Circulatory Support
Occurrence of implantation or initiation of long-term mechanical circulatory support after cohort entry during follow-up, as documented in clinical records. The date and type of mechanical circulatory support will be recorded.
Time frame: 5 years
Rate of Recurrent Serious Ventricular Arrhythmic Events
Frequency and timing of recurrent sustained ventricular tachycardia, ventricular fibrillation, and appropriate ICD therapies after cohort entry during follow-up. Multiple qualifying events occurring in the same patient will be recorded. The number of recurrent events and event rates per person-year will be evaluated using appropriate recurrent-event statistical methods, subject to the availability and completeness of longitudinal clinical and device records. Event types will be documented separately.
Time frame: 5 years
Recurrence of Ventricular Arrhythmia After Catheter Ablation
Occurrence of documented sustained ventricular tachycardia or ventricular fibrillation after clinically indicated catheter ablation among patients who undergo the procedure. Arrhythmia recurrence will be assessed using available electrocardiographic records, ambulatory rhythm monitoring, device interrogation, and clinical follow-up records. Catheter ablation is performed as part of routine clinical care and is not assigned by the study.
Time frame: Up to 5 years
Proportion of Patients With Changes in Ventricular Phenotype
Changes in the predominant pattern of ventricular involvement in patients with arrhythmogenic cardiomyopathy, classified as right-dominant, left-dominant, or biventricular phenotype. The proportion of patients transitioning from one ventricular phenotype to another during follow-up will be assessed based on available clinical and imaging evaluations. Phenotype classification will follow the diagnostic criteria specified in the study protocol.
Time frame: Baseline and up to 5 years
Change in Left Ventricular Ejection Fraction
Change in left ventricular ejection fraction (LVEF, %), assessed using serial echocardiography or cardiac magnetic resonance imaging performed during routine clinical care. Baseline and subsequent measurements obtained using comparable imaging modalities will be compared to evaluate changes in left ventricular systolic function. Analyses will account for the imaging modality used.
Time frame: Baseline and up to 5 years
Change in Right Ventricular Ejection Fraction
Change in right ventricular ejection fraction (RVEF, %), assessed using serial cardiac magnetic resonance imaging when available. Baseline and subsequent RVEF measurements will be compared to characterize longitudinal changes in right ventricular systolic function. Analyses will be restricted to participants with available comparable serial imaging data.
Time frame: Baseline and up to 5 years
Change in Left Ventricular End-Diastolic Volume Index
Change in left ventricular end-diastolic volume index (LVEDVi, mL/m²), assessed using cardiac magnetic resonance imaging when available. Baseline and subsequent measurements will be compared to characterize longitudinal changes in left ventricular size and remodeling. Analyses will be restricted to participants with available comparable serial imaging data.
Time frame: Baseline and up to 5 years
Change in Right Ventricular End-Diastolic Volume Index
Change in right ventricular end-diastolic volume index (RVEDVi, mL/m²), assessed using cardiac magnetic resonance imaging when available. Baseline and subsequent measurements will be compared to characterize longitudinal changes in right ventricular size and remodeling. Analyses will be restricted to participants with available comparable serial imaging data.
Time frame: Baseline and up to 5 years
Presence of Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging
Presence or absence of late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging during follow-up. Changes in LGE status from baseline will be evaluated among participants with available comparable serial cardiac magnetic resonance imaging examinations.
Time frame: Baseline and up to 5 years
Ventricular Distribution of Late Gadolinium Enhancement
Distribution of late gadolinium enhancement on cardiac magnetic resonance imaging, classified according to the ventricular region involved, including right ventricular, left ventricular, or biventricular involvement, based on available imaging assessments. Longitudinal changes in the distribution of LGE will be evaluated among participants with available comparable serial imaging examinations.
Time frame: Baseline and up to 5 years
Associations Between Biospecimen-Derived Molecular Profiles and Clinical Outcomes
Exploratory assessment of associations between molecular characteristics derived from appropriately authorized biological samples and clinical outcomes in patients with arrhythmogenic cardiomyopathy. Depending on sample availability and separately approved research protocols, analyses may include genetic, proteomic, metabolomic, or other molecular measurements. Each molecular measurement will be analyzed separately according to its specific assay and measurement scale. Associations with serious ventricular arrhythmic events, sudden cardiac death, heart failure-related outcomes, and clinical disease phenotypes may be explored. Analyses will be restricted to participants with available, appropriately authorized samples and relevant clinical data.
Time frame: Baseline and up to 5 years
Exploratory Molecular Signatures Associated With Ventricular Remodeling and ACM Phenotypes
Exploratory characterization of molecular signatures potentially associated with myocardial remodeling and clinical phenotype heterogeneity in arrhythmogenic cardiomyopathy. Where appropriately authorized tissue or other biological samples and relevant clinical data are available, separately approved analyses may investigate molecular pathways related to myocardial fibrosis, inflammation, cellular stress, and metabolic remodeling. Findings may be compared across right-dominant, left-dominant, and biventricular ACM phenotypes and examined in relation to available cardiac imaging and longitudinal clinical characteristics. Different molecular measurements will be analyzed separately according to the methods used. No additional invasive procedures will be performed solely for these analyses.
Time frame: Baseline and up to 5 years
Started Apr 2024 (actual). Primary completion is estimated for Dec 2050, 320 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Aug 2030 → Dec 2050 and completion Aug 2032 → Dec 2050.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arrhythmogenic Right Ventricular Dysplasia →
First Affiliated Hospital Xi'an Jiaotong University →